Sign in
Active, not recruitingNo phase

Cardiovascular Effects of Parathyroid Hormone Analogues in Chronic Hypoparathyroidism

Key facts

Who runs it
National and Kapodistrian University of Athens
Where
Greece2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
210 people, planned
Started
1 Apr 2026
Expected to end
31 Dec 2028
Type of study
Observational, 4 groups
Treatments tested
  • Arterial stiffness in the aorta by measurement of pulse wave velocity
  • Central blood pressures and reflected waves in the aorta
  • Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques
  • Imaging of the sublingual microcirculation (GlycoCheck system)
  • Ankle-brachial index (ABI)
  • Fundoscopy
  • Cardiac Ultrasonography Study
  • Local shear stress in brachial and carotid artery
  • Peripheral and aortic office and ambulatory blood pressure
  • Circulating levels of myocardial biomarkers
  • Evaluation of Calcium metabolism
Record updated
16 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Cross sectional arm: Baseline State: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year; -Prospective Follow-up: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy and about to start treatment with palopegteriparatide willing to undergo baseline measurements (prior to the first dose) and repeat measurements at 3 and 12 months

Who cannot take part

  • Bone Health: Any metabolic bone disease other than hypoparathyroidism (excluding osteoporosis)
  • Renal Function: CKD Stage 3 or higher (eGFR < 60 mL/min/1.73 m²)
  • Uncontrolled Risk Factors:; SBP > 180/100 mmHg; Uncontrolled endocrine diseases (e.g., hyper- or hypothyroidism, diabetes mellitus type 2 with HbA1c>7.5%)
  • Documented Atrial Fibrillation (ECG)
  • Contraindication to long acting PTH analogue as per product labeling

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to evaluate cardiovascular effects of long-acting parathyroid hormone (PTH) analogues in adults with chronic hypoparathyroidism. The main questions it aims to answer are:

Read full original descriptionShow less

* Do patients with hypoparathyroidism have increased arterial stiffness and markers of subclinical cardiovascular injury compared to healthy individuals? * Does treatment with a long-acting PTH analogue improve vascular and cardiac function over time compared to conventional therapy? This is a multi-center study with two parts: a cross-sectional comparison and a 12-month prospective follow-up. Adults with chronic hypoparathyroidism and matched healthy controls will undergo clinical evaluation, vascular measurements, cardiac imaging, and blood tests.

In the prospective part, patients that just started long-acting PTH analogue therapy based on their treating physicians choice will be followed for 12 months, with repeat assessments at baseline, 3 months, and 12 months to evaluate changes in cardiovascular markers.

The 4 groups in the trial

  • Patients with chronic hypoparathyroidism under conventional treatment (disease control)

    20-30 Hypo-PT patients aged ≥18 on conventional HypoPT therapy with any dose of activated vitamin D and calcium and native vitamin D supplements for at least 12 months

    Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism

  • Patients with chronic hypoparathyroidism under treatment with palopegteriparatide

    40-50 Hypo-PT patients aged ≥18 treated with Palopegteriparatide (TransCon PTH) for at least 12 months

    Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism

  • Healthy controls

    Healthy controls: 170 Healthy controls matched with group 1 and group 2 for age, sex, CVD presence, propensity score, DM2, renal function, BMI and SBP, retrospectively recruited from the Athens Angiometabolic Cohort

    Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism

  • Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide

    20 patients starting treatment with palopegteriparatide, previously on conventional treatment

    Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Long-acting PTH Analogues on Markers of Subclinical Arterial and Myocardial Injury in Chronic Hypoparathyroidism..
Record updated
16 July 2026